Nirmatrelvir-Ritonavir Effective for Outpatient Treatment of COVID-19
TUESDAY, June 6, 2023 -- For outpatient treatment of COVID-19, nirmatrelvir-ritonavir is effective for reducing 30-day hospitalization or death, while molnupiravir is associated with a reduction in 30-day mortality, according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 6, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves First Oral Antiviral Drug for COVID-19
(MedPage Today) -- The FDA has granted full approval to nirmatrelvir-ritonavir (Paxlovid) for treating adult outpatients with mild to moderate COVID-19 who are at risk for severe disease, the agency announced on Thursday.
"Today's approval demonstrates... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 26, 2023 Category: American Health Source Type: news
FDA Approves Paxlovid (nirmatrelvir tablets and ritonavir tablets) for Adult Patients at High Risk of Progression to Severe COVID-19
NEW YORK--(BUSINESS WIRE) May 25, 2023 -- Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved Paxlovid™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 25, 2023 Category: Drugs & Pharmacology Source Type: news
Pfizer & #039;s PAXLOVID ™ receives FDA approval for adult patients at high risk of progression to severe COVID-19
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) approved PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets) for the treatment of mild-to-moderate COVID-19 in adults who are at high risk for progression to severe COVID-19, including hospitalization or death. PAXLOVID has been available in the U.S. since December 2021 under Emergency Use Authorization (EUA), and the overall benefit/risk profile and indication for use in eligible adults remain consistent with the EUA. (Source: World Pharma News)
Source: World Pharma News - May 25, 2023 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news
What Are the Symptoms of Serotonin Syndrome?
Discussion
Serotonin syndrome (SS) is a clinical diagnosis and problem which can be seen in patients of all ages. Classically SS presents with changing mental status, autonomic dysfunction and neuromuscular excitability. It is caused by increased serotonin levels because of therapeutically increasing the dose of a medication already being taken, adding an additional serotoninergic medication or one that potentiates serotonin, overlapping transition when changing medications, or intentional or unintentional overdose. It has become more common especially as selective serotonin reuptake inhibitors (SSRIs) have been used more ...
Source: PediatricEducation.org - May 8, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Casirivimab plus imdevimab, nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 [TA878], NICE (updated 5th April 2023)
Increased risk for progression to severe COVID added as new recommendation for use for nirmatrelvir plus ritonavir and sotrovimab as per independent advisory group report commissioned by the Department of Health and Social Care. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - April 6, 2023 Category: Consumer Health News Source Type: news
COVID-19 rapid guideline: managing COVID-19 [NG191], NICE (updated 29th March 2023)
This guideline covers the management of COVID-19 for babies, children, young people and adults in all care settings. It brings together our existing recommendations on managing COVID-19, and new recommendations on therapeutics, so that healthcare staff and those planning and delivering services can find and use them more easily.
We are continually monitoring the evidence and updating the guideline as new information emerges.
29 March 2023: In the section on therapeutics for COVID-19 we:
updated recommendations on baricitinib and remdesivir
updated recommendations on casirivimab plus imdevimab, nirmatrelvir plus rit...
Source: Current Awareness Service for Health (CASH) - March 31, 2023 Category: Consumer Health News Source Type: news
Paxlovid May Lower Long COVID Risk, VA Study Suggests
(MedPage Today) -- Use of nirmatrelvir-ritonavir (Paxlovid) in older adults with risk factors for severe disease was associated with a roughly 25% lower risk of a post-COVID condition (PCC), a retrospective study of Veterans Affairs data showed... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - March 24, 2023 Category: Infectious Diseases Source Type: news
FDA Panel Backs Full Approval of Paxlovid for COVID-19
(MedPage Today) -- An FDA panel recommended the agency grant full approval to nirmatrelvir-ritonavir (Paxlovid) for treating high-risk COVID-19.
By a vote of 16-1 on Thursday, the Antimicrobial Drugs Advisory Committee said the totality of evidence... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 17, 2023 Category: American Health Source Type: news
Africa: Malawi, Rwanda and Zambia Receive Covid-19 Treatments for High-Risk Patients
[COVID Treatment Quick Start Consortium] The COVID Treatment Quick Start Consortium announced today that the governments of Zambia, Laos, Malawi and Rwanda have received shipments of PAXLOVID™ (nirmatrelvir/ritonavir), Pfizer's COVID-19 oral treatment. Partners involved in the Quick Start Consortium are supporting test-and-treat programs to improve access to antiviral treatments in low- and middle-income countries. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 16, 2023 Category: African Health Source Type: news
Paxlovid Works in High-Risk COVID, Says FDA Staff, but Drug Interactions a Concern
(MedPage Today) -- Nirmatrelvir-ritonavir (Paxlovid) wards off severe disease in high-risk COVID patients, but drug interactions at the individual level often disfavor its use, said FDA staff in briefing documents released ahead of an advisory... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - March 15, 2023 Category: American Health Source Type: news
Viral, Symptom Rebound Common After COVID-19 Infection
THURSDAY, March 9, 2023 -- COVID-19 rebound is common, even among patients treated with nirmatrelvir plus ritonavir (NPR), according to a study published online Feb. 22 in Clinical Infectious Diseases.
Jay A. Pandit, M.D., from the Scripps Research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 9, 2023 Category: Pharmaceuticals Source Type: news
Late-Breaking Phase 3 A DUE Data Show Investigational Single Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Hemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)
RARITAN, NJ, March 6, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase 3 A DUE study (NCT03904693), which showed an investigational once-daily, single tablet combination therapy, also known as fixed dose combination, of macitentan 10 mg and tadalafil 40 mg (M/T STCT), significantly improved pulmonary hemodynamics (blood flow through pulmonary blood vessels) versus macitentan and tadalafil monotherapies in pulmonary arterial hypertension (PAH) patients with World Health Organization (WHO) functional class (FC) II or III.[1] The data were presented today as a Late-...
Source: Johnson and Johnson - March 6, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
Therapeutics for people with COVID-19 [ID4038], NICE
Draft guideline with the suggested remit: To appraise the clinical and cost effectiveness of remdesivir, tocilizumab, casirivimab and imdevimab, baricitinib, sotrovimab, molnupiravir, anakinra, lenzilumab and nirmatrelvir and ritonavir within their proposed marketing authorisations for treating people with symptomatic coronavirus disease 2019 (COVID-19). (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - February 28, 2023 Category: Consumer Health News Source Type: news
COVID Rebound Not Exclusive to Those on Paxlovid
(MedPage Today) -- SEATTLE -- While SARS-CoV-2 rebound can occur in patients not taking nirmatrelvir-ritonavir (Paxlovid), it was rare and usually only lasted a day, according to a retrospective analysis of the randomized ACTIV-2 trials.
Across... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - February 22, 2023 Category: Infectious Diseases Source Type: news
